Objective: To determine patient experiences of glucocorticoid (GC) therapy in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). Methods: Patients with a diagnosis of PMR or GCA were invited to participate in this qualitative study that used focus groups to explore: symptoms onset, process of diagnosis, treatment, adverse effects (AEs), and ongoing condition/s management. Data were transcribed verbatim and a "framework" approach was used for analysis and interpretation. Results: Fourteen patients participated. Weight gain, changes in face and neck shape, and bruising were commonly reported and impacts of these AEs on quality of life were highlighted. Dealing with uncertainties associated with long-term experiences of the condition/s and cycles of GC treatment were raised as were workload demands for patients in managing both the condition and other people's expectations and recommendations related to GC therapy. Conclusion: These findings demonstrate that the patient experience of GC use is poorly captured by usual physician monitoring for GC AEs. These findings suggest that development of a patientreported outcome instrument for inflammatory conditions treated with GCs is required.
Introduction
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are relatively common rheumatic conditions occurring in older people 1 and while the relationship between these two conditions is not clearly established, approximately 15% of the patients with PMR also develop GCA and around 50% of those with GCA also have associated PMR. 2 Glucocorticoids (GCs) are the current mainstay of therapy for both PMR and GCA with excellent efficacy. However, GC therapy is associated with many potential adverse effects (AEs). In order to minimize these AEs when treating PMR and GCA, the aim is to use the lowest dose possible for the shortest duration necessary to control disease and prevent relapse. 3 However, in clinical practice, patients will often require GC therapy for two or more years, [4] [5] [6] [7] and this accounts for up to a third of elderly people who are taking long-term low dose corticosteroids. 4 Thus, although the overall prognosis of PMR itself can be regarded as good, the inherent and predictable AEs of the GC treatment contribute to a significant health burden.
Some GC AEs, such as fractures, diabetes, and hypertension, are easy to measure and are known to have a significant impact on patients in terms of quality of life, direct, and indirect medical costs. 5 However, other frequent AEs are more difficult to measure and their impact on the quality of life is less understood. It is likely that patients with differing demographics and diagnoses will have different experiences of the beneficial and AEs of GC use. Little is known about how these effects impact on people with PMR and GCA. 6, 7 This study contributes to a larger body of work driven by the OMERACT (Outcome Measures in Rheumatology Clinical Trials) Glucocorticoid Special Interest Group (GC SIG), which aims to develop a patient-reported outcome measure (PROM) for GC therapy. 8 In this preliminary study, the objective was to explore patient experiences of PMR and GCA, along with their perceptions of GC therapy and any associated beneficial and AEs.
Methods

Study design
The overall design for this qualitative study drew on a phenomenological approach emphasizing the embodied experiences of those people living with PMR and GCA. 9 This approach assumes that people create meaning through the experience of moving through space and across time. 9 This non-interventional study used focus groups with patients who had PMR and/or GCA as its method of data collection and a "framework analysis" approach to analyze and interpret the results. 10 
Sample and recruitment
Patients from rheumatology clinics at two Australian tertiary hospitals, The Queen Elizabeth Hospital and the Royal Adelaide Hospital, were invited by letter and information sheet (n=79) to participate in the study. Informed consent was gained via the completion of a signed consent form prior to participation in the focus group. There were 14 participants and of these, 12 attended one of the four focus groups (see details in Table 1 ) with an additional two participants unable to attend on the day, subsequently interviewed individually, by phone. Eligibility criteria for participation were; being at least 18 years old, able to communicate in English, and currently under the care of one of the hospital clinics for PMR or GCA. Given that the incidences of these conditions increase with age (peaking between 70 and 80 years) and women are twice as likely as men to be affected 11 the researchers anticipated that the demographic profile of participants would tend to be older and female, although inclusion of some men and a range of ages were identified as important in sample recruitment.
Data collection
Focus groups, following a semi-structured script (see Table S1 ) were facilitated by an experienced qualitative research fellow (EH) and a clinical trails researcher (CR) with clinical experience in rheumatology. Neither had a clinical relationship with the participants. Focus groups lasted approximately 90 mins and were conducted away from the hospital setting at Arthritis South Australia. This is a charitable organization that works locally to empower people living with arthritis and related conditions, to achieve the best possible quality of life through advocacy, education, self-management, and the support of research. Semi-structured interviews, following the same script as the focus groups, were conducted with two further participants who were unable to attend the focus groups. With consent, focus groups and interviews were audio recorded for later transcription. The requirement for confidentiality of content discussed at each focus group was stressed by the facilitators (and covered in the study information sheet and consent form). Themes discussed were: onset of symptoms, process of diagnosis, treatment, AEs of treatment, and ongoing management of their condition/s. Prior to a focus group, participants were invited to complete a brief questionnaire including demographic data, disease duration, comorbidities, current GC dose, duration of GC dose. Reflexive notes, including impressions of data collection and emergent themes, were used by the researchers in analysis and interpretation. 
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Analysis
All focus group and interview data were transcribed verbatim and a framework analysis 10 approach was used to analyze and interpret the qualitative data. Framework analysis was used as it allowed for both inductive and deductive analysis. The researchers were interested in exploring specific experiences tied adverse events (AEs) associated GC therapy (deductive approach) while also being open to gaining new understandings about subjective experiences and attitudes associated with GC use (inductive approach). The Nvivo10 software was used to code, and refine patterns and relationships in the data. Analysis began with familiarization of the data individually by both clinical and nonclinical researchers. Open coding of the transcripts was used to account for multiple perspectives and themes (related to emotions, values, and experiences) while a specific theme tied to AEs was also examined as this had been a topic of interest in the design of the study. As a team, four of the five researchers then met face-to-face to compare their individual open and specific coding of separate focus group transcripts and to begin testing and refining an agreed coding framework. Patterns and relationships were used to develop and apply a working thematic framework for all transcripts. Table S2 outlines the way coding developed to identify and test these themes. Potential major themes that were supported by data from multiple participants (data triangulation) were then discussed by the researchers to form a consensus on the themes to be reported. In the interpretation stage triangulation of the findings with other analyses were used to test the rigor of the findings.
Results
Patient sample characteristics
Of the 14 participants, 1 was aged less than 65 years, 10 were between 65 and 74 years, and 3 were over 75 years. Participants were most likely to be women (n=9) and all but two reported having at least one other health condition. Diagnosis ranged from 2000 to 2014, and six were currently on GC therapy, see Table 1 .
Themes of findings
AEs of GC therapy
While a few participants (n=3) reported that they had not experienced any AEs associated with GC treatment, the majority of participants reported at least some, with a wide range identified (see Table 2 ). A key characteristic of these data on AEs was the prominence of those associated with appearance, with bruising, face and neck shape, and weight gain frequently cited. As the quotes demonstrate, the impact of AEs on participants' everyday lives and their wellbeing was an important aspect of their descriptions. For example, when participants talked about bruising, several dimensions of their effects were identified, not only pain and unsightliness, but also the impact of bruises on both their workplace and personal relationships. The example quotes (Table 2) highlight the emotive language used to describe difficult everyday interactions that resulted. In relation to weight gain, language such as "hate myself", and "I was hungry all the time" were used to describe how some participants felt about this AE. It is of note that these descriptions were described in the context of high GC doses and that the participants perceived that AEs were dose dependent. Further, the AEs that were described (see Table 2 ) tended to occur after an initial positive treatment effect.
Managing uncertainties
Across multiple analysis nodes, an underlying theme of managing uncertainties related to the condition/s and treatment was commonly expressed. The uncertainties of living with the condition long term, dealing with cycles of GC treatment, managing the warning signs of flares, and distinguishing symptoms of the condition from other health issues, were all raised. For example, when discussing how he selfmonitored for symptoms when reducing his GC dose, a male participant also inferred a level of uncertainty in relation to how his body (his system) responded, (quote 1, Table 3 ). Another participant noted that: I get aches and pains and I think, oh, is that [PMR] coming back again? A further participant, in recounting the process of tapering the GC dose, recognized that "twinges" may not be related to his condition, but rather other everyday activities. In response to this uncertainty, the participant reported that he increased his GC dosage slightly (quote 2, Table 3 ).
Managing other people's expectations and recommendations relating to GC therapy
A third prevailing theme in the data related to the expression of distrust and concern about GC therapy. Specifically, participants from all four focus groups reported that both clinicians and family and friends had conveyed concern about GC therapy. Participants also explained how they had managed this distrust. For example, following diagnosis of PMR and commencement of GC treatment by a replacement clinician, a participant's usual GP refused to continue to prescribe the therapy (quote 3, Table 3 ). The participant's account highlights the emotive language used by the clinician and the need for him to arrange care by the other GP to overcome this distrust of GCs. Distrust of GC therapy was also reported from family and friends, as shown in quote 4, Table 3 . Participants reported that they managed distrust expressed by clinicians at the same time as experiencing positive treatment effects themselves (quote 5, Table 3 ). This theme highlights an additional burden for patients in managing responses and recommendations from both clinicians and others, to their condition and therapy.
Discussion
This study has provided insights into how GC therapy affects the lives of patients with PMR/GCA. Its findings corroborate results from other qualitative work conducted for the OMERACT 2016 SIG meeting 8 by identifying a common set of AEs associated with GC therapy. Further, findings emphasized the importance of AEs related to appearance and highlighted how patients' subjective understandings of these may affect their embodied selfidentities and perceptions of personal and work relationships, and thereby their quality of life. By extending our understanding beyond a classification of literal AEs to their extended effects on quality of life, this study may inform the development of a PROM for GC therapy. 8 The two further dominant themes identified; managing uncertainties related to the condition and GC therapy, including difficulties distinguishing between the impacts of the condition and the therapy; and managing other people's expectations and recommendations relating to GC therapy, illuminate the particular demands and responsibilities associated with managing PMR and GCA, and their therapy. As Shippee et al, 12 have argued, patients' "workload" may encompass a wide range of demands, related to their role as a patient (eg, self-care, taking medications, attending appointments) and beyond. Shippee et al, contend that where accumulated workload exceeds the capacities of a patient, their engagement with clinicians, quality of life, health outcomes may be affected. It is therefore important that the design and development of a PROM captures the types of workload burdens reported here, in order to inform clinical practice and effectively support patients. Further specific research would be useful to understand the sense of conflict patients describe when clinicians recommend tapering, while they feel they need ongoing GC therapy.
Limitations
Although a range of perspectives were gathered, the current study sampled a small number of participants. Despite the sample being drawn from two large public outpatient clinics in the state, participant recruitment was a challenge. This may reflect the age of the target population, and the socioeconomic profile of public patients attending these clinics. As these clinics are major providers of health care for people with these conditions, it is, however, important to conduct and report research that explores the lived experiences of this hard-to-reach population. Given the small sample, the findings may not be representative of all patients with PMR/GCA and CG therapy. It is also important to note that the number of themes identified may be restricted by the number of participants in the sample. However, there were important commonalities between the findings of this exploratory study and another, which was conducted in the UK and presented at the 2016 OMERACT meeting. 8 These studies informed the development of a specific research agenda to progress a patient-reported outcome instrument for inflammatory conditions treated with GCs.
Ethics approval and consent to participate
The study was approved by The Queen Elizabeth Hospital Human Ethics Committee (HREC/14/TQEH/265) with reciprocal ethics clearance from both the University of 
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Participants reported that both clinical and family and friends (community) expressed distrust and concern about GC therapy.
Across these codes an underlying theme of uncertainty was expressed in relation to: 
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